Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4... Show more
TAK broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 36 similar instances where the stock broke above the upper band. In 20 of the 36 cases the stock fell afterwards. This puts the odds of success at 56%.
The 10-day RSI Indicator for TAK moved out of overbought territory on September 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 12 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 34%.
The Moving Average Convergence Divergence Histogram (MACD) for TAK turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 17 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 40%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on September 11, 2026. You may want to consider a long position or call options on TAK as a result. In 32 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 34%.
The 50-day moving average for TAK moved above the 200-day moving average on August 10, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +2.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where TAK advanced for three days, in 149 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 48%.
The Aroon Indicator entered an Uptrend today. In 149 of 273 cases where TAK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.185) is normal, around the industry mean (46.728). P/E Ratio (41.878) is within average values for comparable stocks, (93.360). Projected Growth (PEG Ratio) (0.401) is also within normal values, averaging (1.931). Dividend Yield (0.034) settles around the average of (0.030) among similar stocks. P/S Ratio (1.918) is also within normal values, averaging (176.516).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. TAK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 50 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a pharmaceutical products manufacturer
Industry PharmaceuticalsGeneric